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Introduction: 
 
Intracellular signaling contributes extensively to the diversity of developmental 
programs and adaptation responses in metazoans. In humans, defects in intracellular 
signaling can cause various diseases, e.g., cancer, neurodegeneration, or diabetes. Thus, 
understanding the structure, function, and evolution of signal transduction is an 
important task for both basic research and medicine. 
Signaling pathways transduce the information of various extracellular ligands to 
the nucleus via receptors, secondary messengers and transcription factors. In the nucleus 
specific changes in gene expression occur as a response to the external stimuli. 
Interestingly, the number of signaling pathways is low and each pathway is formed by 
only 10-20 proteins. Thus, these numbers are contradictory to the overall scale of cell 
types and responses that is governed by signaling pathways. 
Currently, high-throughput (HTP) experiments are the major sources of known 
protein-protein interactions. However, so far in most HTP experiments extracellular, 
membrane-bound, and nuclear proteins have been underrepresented. These and other 
sampling biases strongly reduce their usability for identifying signaling interactions. 
Another limitation of HTP assays is that they produce undirected interactions even 
though in signaling directions are essential. Accordingly, several signaling pathway 
databases have been created recently by manually collecting the directed interactions 
from the literature. 
Manually curated signaling pathway databases are often assembled without 
strictly defined and published standardized curation criteria. Therefore, even within the 
same database, e.g., in KEGG, the level of detail of curation and the rules for setting 
pathway boundaries can vary among pathways. In addition, in several signaling 
resources the definition of signaling pathways has no evolutionary or biochemical 
background. In other cases, e.g., in Reactome and NetPath, curation criteria are 
standardized, however, (i) pathways are usually handled as separate entities, (ii) cross-
talks and multi-pathway proteins are underrepresented, and (iii) extracting signaling 
information from the databases are complicated and labor-intensive. Another limitation 
of several current signaling resources is that they neglect the importance of multi-
pathway proteins, i.e., proteins functioning in more than one pathway. In summary, the 
manual curation process needs to be uniform across all pathways and species to aid 
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cross-talk analyses, tests of evolutionary hypotheses, dynamical modeling, setting up 
predictions, and drug target selection.  
Intracellular signaling was originally regarded as an assembly of distinct and 
almost linear cascades. Over the past decade, however, it has been realized that 
signaling pathways are highly structured and intertwined with cross-talks (where cross-
talk is defined here as a directed physical interaction between pathways). Consequently, 
intracellular signaling is now viewed as a set of intertwined pathways forming a single 
signaling network. This paradigm shift calls for novel experimental, curation, and 
network modeling techniques. 
 
Aims of the work: 
 My aim was to compile a signaling pathway database that is: 
 novel and can facilitate modern signaling research, including network 
approaches, 
 based on well defined pathways and can be generally used. 
Creation, visualization and validation of such a database requires:  
 the selection of specific organisms and pathways, where adequate amount of 
information is accessible, 
 a curation protocol, that is reproducible and objective, 
 the development of novel visualization methods. 
Beside the creation of this database, I intended to perform analyses that were not 
possible before. Thus, my aim was to illustrate and prove that the newly developed 
database: 
 is a proper source for system-level analyses, 
 can facilitate cross-species comparison of signaling pathways and prediction 
of novel protein functions, 
 allows the analysis of cross-talks between signaling pathways and the 
identification of multi-pathway proteins, 
 is an efficient source for applied research and development approaches (e.g., 
cancer research, drug development). 
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Methods: 
SignaLink lists signaling proteins and directed signaling interactions between 
pairs of proteins in healthy cells of Caenorhabditis elegans, Drosophila melanogaster, 
and Homo sapiens. Each interaction is documented with the PubMed ID of the 
publication reporting the verifying experiment(s). SignaLink was compiled separately 
for the 3 organisms. SignaLink assigns proteins to signaling pathways using the full 
texts of 170 pathway-based reviews. Interactions were curated from a total of 941 
articles (PubMed IDs are included in the database). We selected 8 major pathways for 
curation that have central roles in both development and normal cellular signaling. The 
curation protocol allowed a protein to be assigned to more than one pathway, thus we 
could list multi-pathway proteins. 
Due to the absence of appropriate gold standards we compared the human 
signaling pathways of SignaLink with those from 3 widely used pathway databases: 
KEGG, Reactome, and NetPath. For reference we compared the human signaling 
pathways of these three databases to each other too. 
We visualized the signaling pathways and cross-talk of SignaLink with 
traditional and novel visualization methods. This was necessary to illustrate and 
examine the signaling network. Altogether, we have applied 7 visualization methods 
based on the signaling, orthology and cross-talk properties of the network components. 
In each of the three species examined, we listed those proteins that have no 
known signaling interactions but have at least one signaling pathway member ortholog 
in the other two species. Similarly to the concept of functional orthology, for each of 
these proteins we assumed that their pathway annotations (i.e., signaling role) can be 
transferred between species. In other words, we predicted that such a protein is a 
member of the signaling pathway(s) to which its ortholog(s) in the organism belong(s). 
These proteins were termed as signalog proteins (signalogs). 
To investigate the dynamic activity of pathway interactions, we selected five 
healthy tissue types – colorectal, muscle, skin, liver, and cardiovascular tissues – and 2 
liver carcinomas. Protein expression data in healthy tissue types were downloaded from 
the eGenetics database. Protein expression data in 2 screens of liver carcinomas were 
obtained from Oncomine 3.6. We considered a protein differentially expressed if the p 
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value of its expression in at least one of the 2 screens, as compared to healthy liver 
tissues and computed by a t-test of Oncomine, was below 0.05. 
We collected information on the proteins that can be relevant in drug target 
discovery with DAVID. We downloaded disease-related annotations from OMIM, 
GAD, and Orthodisease, domain information from InterPRO, and molecular function 
and cellular component data from GO. 
 
Results: 
 1. The SignaLink database 
We curated the signaling pathways of the nematode Caenorhabditis elegans, the 
fruit fly Drosophila melanogaster, and Homo sapiens. From the wide variety of 
classification schemes for selecting signaling pathways we followed the biochemical 
approach of Pires-daSilva and Sommer. We selected 8 major pathways for curation – 
EGF/MAPK, Ins/IGF, TGF-β, WNT, Hh (Hedgehog), JAK/STAT, Notch, and NHR 
(Nuclear Hormone Receptors) – that have central roles both in development and in 
normal cellular signaling. 
SignaLink is a manually compiled resource integrating experimentally 
confirmed genetic and physical interactions from healthy tissue types. Proteins and 
interactions are listed without tissue-specificity and can be visualized as networks of 
potential interactions. Tissue- and disease-specific information can be added easily as 
shown in the examples below. Five combined characteristics create the unique utility of 
SignaLink:  
 Pathways are biochemically defined and encompass all major developmental 
signaling mechanisms; 
 A protein can belong to more than one pathway (if it does, then it is called a 
multi-pathway protein); 
 Proteins are tagged with (i) the pathway(s), (ii) pathway region(s) (core, 
peripheral), and (iii) the pathway sections (one or two of: ligand, receptor, 
mediator, co-factor, transcription factor, other) they belong to; 
 The level of detail is the same for the entire database; 
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 Interactions are directed and manually labeled with PubMed IDs (experimental 
evidence). 
The current version of SignaLink (published in 2010) contains 442, 211, and 525 
proteins in C. elegans, D. melanogaster, and humans, respectively. Between these 
proteins it contains 237, 233, and 991 interactions, respectively. The SignaLink 
database can be freely accessed at http://SignaLink.org.  
 
2. Comparing SignaLink database with other pathway databases  
 
There are currently no gold standards compiled with similar goals and methods 
as SignaLink. It is therefore important to compare both the curation protocols and the 
actual data of several available databases before selecting one of them for a particular 
analysis. We compared three widely used pathway databases – KEGG, Reactome, and 
NetPath – and SignaLink. In each pairwise comparison we used the pathways available 
in both databases. 
According to this comparison, SignaLink has the following advantages 
compared to the three analyzed databases:  
 precisely defined and documented curation protocol;  
 highest numbers of signaling proteins and interactions in the curated 
signaling pathways;  
 highest numbers of cross-talks and multi-pathway proteins;  
 largest protein overlap with the other databases;  
 above the average number of publications used per pathway. 
 
3. Visualization of the SignaLink database 
Altogether, we have applied 7 visualization methods based on the signaling, 
orthology and cross-talk properties of the network components. Color was the main 
differences between the traditional, protein-based network visualization approaches 
(e.g., we colored the proteins and their interactions based on their pathway or signaling 
position property). We created 8-8 pathway images for the 3 species. All the network 
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images can be interactively explored at http://SignaLink.org. To visualize the cross-talk 
networks we applied 3 different approaches: 
 A network visualization where each node represent a pathway (a set of proteins) 
and the edges between the nodes represent cross-talks (a set of protein-protein 
interactions). Coloring was done based on signaling or orthology properties. 
 We created an interaction matrix, where specific cross-talks are present in each 
cell. In this case to color the cells, we used expression data of proteins. 
 Finally, multi-pathway proteins were visualized: each node represents a 
pathway, and the edges between these nodes represent the overlaps between the 
pathways (not the interactions as in the first approach). 
 
 
4. Results of the analyses performed with SignaLink  
 
The newly developed SignaLink database has properties not present in other 
signaling pathway databases and its quantitative and qualitative features allow the 
system-level analysis of signaling networks. 
4/a Identification and analysis of novel gene functions  
We identified novel signaling pathway components based on the signaling 
pathway memberships of orthologs in another organism. We found 88, 92, and 73 
proteins in C. elegans, D. melanogaster and H. sapiens, respectively, which had 
previously not been assigned to a signaling system, but have at least one ortholog in the 
other two species that is clearly associated with a signaling pathway. We hypothesized 
that these 253 proteins function in the same signaling pathways as their orthologs. Thus, 
we named the predicted signaling components signalog proteins, or briefly signalogs. 
The complete list of signalogs can be accessed at http://SignaLink.org. We examined 
the novelty of the signalogs, and verified their novelty.  
4/b Comparison of signaling pathways within and between species 
In all 3 organisms a few of the 8 pathways are central and abundant. Of all 
proteins 26% to 38% participate in the EGF/MAPK and WNT pathways, respectively. 
Other pathways with high protein numbers are NHR in the worm, Hh and Notch in the 
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fly, and TGF and JAK/STAT in humans. Altogether in each species 68% to 85% of all 
signaling proteins participate in these pathways and 56% to 70% of all cross-talks 
involve the EGF/MAPK, TGF, or WNT pathways. C. elegans has almost identical 
numbers of core and peripheral proteins in each pathway (except for Notch and NHR), 
while in the other two species the ratio of core to peripheral proteins is around 1.5. 
Pathway size differences between the 3 species are often related to the different 
environments to which the cells of these organisms have adapted. For example, ligands 
from the environment can easily reach the nuclei of the worm’s cells, thus, the worm’s 
NHR pathway is exceptionally large (58% of all signaling proteins). On the other hand, 
due to the large variety of signals that human cells are exposed to the human 
JAK/STAT pathway is oversized com-pared to the other two species (21% of all 
signaling proteins in humans vs. 0% and 4% in C. elegans and Drosophila, 
respectively). 
In all 3 species EGF/MAPK and IGF have high numbers of mediators. However, 
environmental differences may affect pathway section sizes too. In C. elegans 
transcription factors – dominated by the NHR pathway – are the largest pathway section 
(39%). In the other two species co-factors by far outnumber other pathway sections 
(32% to 42%) and in humans JAK/STAT ligands and receptors are abundant. 
 
4/c Identification and analysis of multi-pathway proteins 
In C. elegans, D. melanogaster, and humans, we found 6, 12, and 62 multi-
pathway proteins, respectively. Within one human signaling pathway the ratio of 
proteins functioning in at least one other pathway varies from 5% (Notch) to 46% 
(IGF). Interestingly, a single protein can be even a central (i.e., core) component in 
more than one pathway.  
We found that EGF/MAPK – the largest pathway – is the only one sharing 
proteins with all other pathways. On the other end of the spectrum are the Notch, 
JAK/STAT, and NHR pathways: their proteins are contained by 3 or 4 other pathways. 
These differences correlate well with the numbers of pathway functions. Note also that 
the set of 62 human multi-pathway proteins is enriched with disease-related proteins: 
45% (28) of them are known to be disease-related, while in the 8 human signaling 
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pathways only 25.5% (165 of 646) and among all human proteins listed by Ensembl 
only 20% (3,929 of 19,534). For both comparisons p < 0.001. 
 
4/d Cross-species comparison of cross-talks 
In C. elegans only 6 of the 8 curated pathways are active, and the Notch pathway 
is isolated. In addition, the cross-talk network of the pathways – where nodes represent 
pathways and links represent cross-talks – is sparse. Between the 6 active pathways 
only 5 of the 30 ( = 6×5 ) possible cross-talk types are present. In Drosophila all 8 
curated pathways of SignaLink are active, but the NHR and JAK/STAT pathways are 
still isolated. Without these two pathways the cross-talk network is already significantly 
denser than in the worm: 16 of the total 30 possible cross-talk types are present. In 
humans – the most complex organism of the three – all 8 curated signaling pathways are 
active and almost all of the 56 possible cross-talk types are possible. The ubiquity of 
cross-talks (all 28 pathway pairs can cross-talk) expands both the repertoire of possible 
phenotypes and the system-level responses to environmental and pathological changes. 
In C. elegans cross-talk is possible through receptors, mediators, and 
transcription factors. In the other two species all pathway sections can participate in 
cross-talk, except for the NHR and JAK/STAT pathways of Drosophila, where cross-
talk occurs mostly at the transcriptional level and through mediators.  
The presence of cross-talks in many pathways and pathway sections is a sign of 
the efficient utilization of resources: expanding the functions of an already existing 
pathway protein is more efficient than evolving a novel protein. In addition to the 
number of active pathways and cross-talks a further important indicator of signaling 
complexity is the number of cross-talks relative to all signaling interactions. In the 
worm 4.6% of all signaling interactions are cross-talks, in the fly 10.5%, and in humans 
30.3%. Interestingly, the growth of the number of cross-talks from worm to fly and 
human is not simply due to the growth of the number of protein-coding genes (20 100, 
13 800, 23 000, respectively) or the number of signaling-related PubMed articles (3 
889, 11 367, 214 193 in worms, flies, and humans, respectively). 
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4/e Tissue- and disease-specific activity of cross-talks 
Cross-talks, similar to other protein-protein interactions, are not active 
permanently in all tissue types. We considered an interaction to be possibly active in a 
given tissue type, if both of the mRNAs of its participating proteins are expressed in 
that tissue. The following pairs of large pathways the ratio of active signaling cross-
talks is lower than the average: EGF/MAPK-IGF, IGF-JAK/STAT, EGF/MAPK-
JAK/STAT, IGF-TGF, and IGF-WNT. In contrast for 3 larger (and several smaller) 
pairs of pathways cross-talk is more frequent in the investigated tissue types than one 
would assume from the sizes of the two cross-talking pathways: EGF/MAPK-NHR, 
NHR-TGF, and NHR-WNT. Cancers are often viewed as systems diseases. In cancer 
cells large-scale modifications of signaling pathways, especially changes of cross-talks, 
are prevalent. We considered a signaling interaction to be altered in liver carcinomas, if, 
compared to healthy liver tissues, at least one of the participating proteins was 
differentially expressed. In 3 of the 8 pathways (WNT, NHR, and JAK/STAT) only 
~30% of all proteins were differentially expressed in the investigated liver carcinomas, 
while in the other 5 pathways this ratio was ~50%. 
Finally, we concluded that the pathways EGF/MAPK, JAK/STAT, and Notch 
are clear examples for three distinct types of signaling behavior: (i) high expression in 
normal tissue types and strong changes in cancer, (ii) high expression, but small 
changes, and (iii) low expression with small changes.  
 
4/f Suggesting novel drug targets 
We analyzed the drug target relevance of human signaling proteins by examining 
4 key properties: disease-relatedness, localization in the plasma membrane, enzymatic 
functions, and kinase domain content. To identify the most promising drug target 
candidates from the following two sets: (i) list of novel signaling proteins, (ii) human 
multi-pathway proteins and proteins participating in cancer-related cross-talks. Some of 
these proteins could be specific and proper targets, some of them could be too central 
and aspecific. 
Analysis of signalogs predicted signaling pathway memberships for 5 currently 
used drug target proteins and suggested 14 additional proteins that can be used as novel 
drug target candidates.. Our predictions may (i) reveal novel therapeutic intervention 
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points (e.g., the use of signalogs as novel targets to block specific pathways); (ii) 
suggest novel applications of current drugs to diseases, where the newly predicted 
signaling pathway of their target is relevant, and (iii) help to identify possible side 
effects of currently used drugs. 
After listing the properties of multi-pathway proteins and proteins participating 
in cancer-related cross-talks relevant for drug target selection, we suggested 4 novel 
drug target candidates. One of them, ROR2, was recently proposed as a novel 
chemotherapeutic target, while the other 3 are known to be non-specifically affected by 
anti-inflammatory drugs. 
 
Summary: 
 
1. We developed a signaling pathway database, called SignaLink. Its uniform 
curation rules and data structure allow the system-level examination of the 
signaling network. SignaLink contains the signaling pathways of 3 metazoans, 
the nematode C. elegans, the fruit fly D. melanogaster, and humans. 
2. We compared SignaLink with 3 existing pathway databases. SignaLink was 
found to be better both in quantitative and qualitative properties.  
3. We created several novel methods to visualize signaling networks.  
4. We identified 253 novel signaling proteins, called signalogs, and verified their 
novelty. 
5. We compared the pathways and their cross-talks, and found that only in 
humans every pathway can cross-talk. We found that in humans, cross-talk 
expression is tissue and disease-specific, which underscores its importance in 
development and medicine. We could identify 3 cross-talk expression types. 
6. Examination of signalogs, multi-pathway proteins, and proteins important in 
cross-talks of cancer cells, allowed us to create a short list of possible novel 
drug targets. 
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